Navigation Links
Cedars-Sinai opens new Induced Pluripotent Stem Cell Core Production Facility
Date:9/29/2011

LOS ANGELES The Cedars-Sinai Regenerative Medicine Institute has opened a new Induced Pluripotent Stem Cell (iPSC) Core Facility to produce powerful cells capable of making all tissues of the body from adult human skin cells.

One of the first to open in California, cells produced by the Cedars-Sinai core will be used in research funded by the National Institutes of Health and the California Institute for Regenerative Medicine. The cells will be critical for innovative research aimed at increasing our understanding of human diseases and genetic disorders, and the quest for new treatments.

"The opening of the Cedars-Sinai Stem Cell Core Facility underscores what an exciting time this is in regenerative medicine," said Shlomo Melmed, MD, senior vice president of academic affairs and dean of the faculty at Cedars-Sinai. "It also is an example of Cedars-Sinai's deep commitment to the scientific research that will be translated into tomorrow's leading-edge treatments."

The new facility will use the latest technology to generate induced pluripotent stem cells from a patient skin scraping. The induced pluripotent stem cells can be replicated indefinitely and have biological properties similar to embryonic stem cells. These "blank slate" cells can then be turned into any kind of differentiated cell, such as a brain cell or an eye cell or a liver cell.

Although iPS cells were first produced only three years ago, they have quickly become valuable research tools. Clinicians can take skin cells from patients with specific life threatening diseases. Then, Regenerative Medicine Institute scientists can create iPS cells from them and then generate so-called "disease in a dish" models that enable them to more easily identify effective therapies.

"Now, for the first time, we can study human diseases by creating a laboratory specimen of afflicted cells," said Clive Svendsen, PhD, director of the Cedars-Sinai Regenerative Medicine Institute. "We have been funded by both the National Institutes of Health and the California Institute of Regenerative Medicine to do this work which has the potential to revolutionize medicine."

For example, the Stem Cell Core Facility already is supplying iPS cells to a five-member National Institutes of Health consortium of researchers for development of potential therapies to treat Huntington's disease, an incurable neurodegenerative genetic disorder that affects muscle coordination and some cognitive functions, such as memory. With funding from the California Institute for Regenerative Medicine, the Cedars-Sinai core has also generated iPS cells from children with spinal muscular atrophy a lethal disease that leaves children paralyzed. These are being used to develop novel drug compounds to treat this devastating disorder,

"We are very excited to launch this new core facility," said Dhruv Sareen, PhD, the core's new director. "It will enable exciting studies across the entire Cedars-Sinai Medical Center and we look forward to much productive collaboration."


'/>"/>

Contact: Sally Stewart
Sally.stewart@cshs.org
310-248-6566
Cedars-Sinai Medical Center
Source:Eurekalert

Related biology news :

1. IronKey Opens New European Office
2. Singapore opens Fusionopolis, its second major R&D hub in 5 years
3. Climate change opens new avenue for spread of invasive plants
4. Orangutans spontaneous whistling opens new chapter in study of evolution of speech
5. Registration Opens for 2009 Force Protection Equipment Demonstration
6. Unexpected finding opens up new way to stop autoimmune diseases and transplant rejection
7. A research work on molluscs nacre opens new doors for its possible use in biomedicine
8. The Earth Observatory of Singapore devoted to the study of earth sciences officially opens
9. Tiny tool to control growing blood vessels opens new potential in tumor research
10. Mobile Communication Market Opens up for Biometrics - Precise Biometrics Awarded 1st Prize at GSMA World Mobile Congress
11. Genital stimulation opens door for cryptic female choice in tsetse flies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
Breaking Biology Technology: